Sudhir Agrawal
Overview
Explore the profile of Sudhir Agrawal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
1741
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Williams L, Gerber D, Elder A, Tseng W, Baru V, Delaney-Busch N, et al.
Mol Ther Nucleic Acids
. 2022 Jul;
29:189-203.
PMID: 35860385
Mutations in the gene are the cause of an ultra-rare neurological disorder characterized by intellectual disability, impaired speech, motor delay, and hypotonia evolving to spasticity, central sleep apnea, and premature...
3.
Agrawal S, Kandimalla E
Immunooncol Technol
. 2022 Jun;
3:15-23.
PMID: 35757301
Recently, it has become clear that the tumour microenvironment (TME) is important in cancer immunotherapy. While immune checkpoint inhibitors are effective for some patients, the heterogeneous nature and status of...
4.
Gait M, Agrawal S
Methods Mol Biol
. 2022 Feb;
2434:3-31.
PMID: 35213007
This introduction charts the history of the development of the major chemical modifications that have influenced the development of nucleic acids therapeutics focusing in particular on antisense oligonucleotide analogues carrying...
5.
Zhang Y, Quraishi I, McClure H, Williams L, Cheng Y, Kale S, et al.
FASEB J
. 2021 Nov;
35(12):e22053.
PMID: 34820911
Mutations in KCNC3, the gene that encodes the Kv3.3 voltage dependent potassium channel, cause Spinocerebellar Ataxia type 13 (SCA13), a disease associated with disrupted motor behaviors, progressive cerebellar degeneration, and...
6.
Agrawal S
Biomedicines
. 2021 Jun;
9(5).
PMID: 34063675
Over the last four decades, tremendous progress has been made in use of synthetic oligonucleotides as therapeutics. This has been possible largely by introducing chemical modifications to provide drug like...
7.
Haymaker C, Johnson D, Murthy R, Bentebibel S, Uemura M, Hudgens C, et al.
Cancer Discov
. 2021 Mar;
11(8):1996-2013.
PMID: 33707233
Many patients with advanced melanoma are resistant to immune checkpoint inhibition. In the ILLUMINATE-204 phase I/II trial, we assessed intratumoral tilsotolimod, an investigational Toll-like receptor 9 agonist, with systemic ipilimumab...
8.
Agrawal S
Trends Mol Med
. 2020 Sep;
26(12):1061-1064.
PMID: 32988738
RNA therapeutics are finally taking their place as a main drug category alongside small molecules and proteins. Here, we follow the twists and turns on their road to success and...
9.
Wang D, Jiang W, Zhu F, Mao X, Agrawal S
Int J Oncol
. 2018 Jun;
53(3):1193-1203.
PMID: 29956749
The objective of cancer immunotherapy is to prime the host's immune system to recognize and attack malignant tumor cells. IMO‑2125, a Toll‑like receptor 9 (TLR9) agonist, exhibited potent antitumor effects...
10.
Welten S, de Vries M, Peters E, Agrawal S, Quax P, Nossent A
Mol Ther Nucleic Acids
. 2017 Jun;
7:61-70.
PMID: 28624225
Improving the efficacy of neovascularization is a promising strategy to restore perfusion of ischemic tissues in patients with peripheral arterial disease. The 14q32 microRNA cluster is highly involved in neovascularization....